West Pharmaceutical Services, Inc. $WST Shares Sold by Bamco Inc. NY

Bamco Inc. NY trimmed its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 12.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 263,189 shares of the medical instruments supplier’s stock after selling 37,742 shares during the quarter. Bamco Inc. NY’s holdings in West Pharmaceutical Services were worth $72,414,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Empowered Funds LLC grew its position in West Pharmaceutical Services by 16.1% in the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after acquiring an additional 224 shares during the period. Intech Investment Management LLC raised its position in West Pharmaceutical Services by 27.7% in the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock valued at $1,348,000 after purchasing an additional 1,307 shares during the period. Acadian Asset Management LLC lifted its stake in shares of West Pharmaceutical Services by 14.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock valued at $284,000 after purchasing an additional 157 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of West Pharmaceutical Services by 78.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock valued at $98,000 after purchasing an additional 197 shares during the last quarter. Finally, First Trust Advisors LP increased its position in shares of West Pharmaceutical Services by 168.4% during the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock worth $10,137,000 after purchasing an additional 29,067 shares during the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

WST has been the topic of a number of recent analyst reports. Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price on the stock. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Stephens reaffirmed an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $340.09.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $323.12 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.71 and a quick ratio of 2.04. The company has a market cap of $22.83 billion, a P/E ratio of 43.20, a P/E/G ratio of 2.76 and a beta of 1.18. The stock has a 50-day moving average of $303.30 and a two-hundred day moving average of $272.66. West Pharmaceutical Services, Inc. has a 1-year low of $206.80 and a 1-year high of $336.82.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.